Precision oncology company Guardant Health (Nasdaq: GH) has announced a strategic collaboration with Pfizer (NYSE: PFE) to support the development and commercialization of the US pharma giant’s cancer portfolio using the Guardant Infinity smart liquid biopsy platform.
Under the multi-year collaboration agreement, the companies aim to use Guardant’s portfolio of liquid biopsy tests in Pfizer’s global clinical studies.
They will also evaluate the clinical utility of circulating tumor DNA level as a surrogate endpoint to monitor therapy response along with related blood-based epigenomic analyses.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze